Vimarsana
Biggest News Aggregation in the World

Page 32 - Study Design News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Study Design. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Study Design Today - Breaking & Trending Today

atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant Depression - Vimarsana News

atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant Depression

Atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant DepressionNEW YORK and BERLIN, Jan. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “the Company”), a clinical-stage biopharmaceutical company focused on mental h...

Clinical characteristics and outcome of Covid-19 illness and predictors of in-hospital mortality in Saudi Arabia | BMC Infectious Diseases - Vimarsana News

Clinical characteristics and outcome of Covid-19 illness and predictors of in-hospital mortality in Saudi Arabia | BMC Infectious Diseases

Patients’ race and ethnicity may play a role in mortality from Covid-19. Studies in China, the US, and Europe have been conducted on the predictors of Covid-19 mortality, yet in the EMR countries, such studies are scarce. Therefore, we aimed to describe the hospitalization rate, ICU-admission, and in-hospital mortality of Covid-19 and predictors of in-hospital mortality in Saudi Arabia. E-medical records were examined for all Covid-19 patients diagnosed in five tertiary hospitals affiliated with the Saudi-National Guard-Health Affairs during March 21, 2020, and September 12, 2021, based ...

Celcuity Inc.: Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Patients with Advanced Breast Cancer at the 2022 San Antonio Breast Cancer Symposium - Vimarsana News

Celcuity Inc.: Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Patients with Advanced Breast Cancer at the 2022 San Antonio Breast Cancer Symposium

High response rates and encouraging median progression free survival rates were observed in patients regardless of PIK3CA mutation statusMedian progression free survival (PFS) of 42.3 months was reported

BioArctic: Results from lecanemab confirmatory phase 3 Clarity AD study to be presented at 15th Clinical Trials on Alzheimer's Disease (CTAD) conference - Vimarsana News

BioArctic: Results from lecanemab confirmatory phase 3 Clarity AD study to be presented at 15th Clinical Trials on Alzheimer's Disease (CTAD) conference

BioArctic: Results from lecanemab confirmatory phase 3 Clarity AD study to be presented at 15th Clinical Trials on Alzheimer's Disease (CTAD) conference - read this article along with other careers information, tips and advice on BioSpace

Clinical Trials Market to be Worth $78.3 Billion by 2030: Million Insights - Vimarsana News

Clinical Trials Market to be Worth $78.3 Billion by 2030: Million Insights

/PRNewswire/ -- The global clinical trials market valued USD 47.0 billion in 2021 and is anticipated to exhibit growth at a CAGR of 5.8% from 2022 to 2030. The...